Picture EBD Group ChinaBio Partnering Forum 2025 Shanghai 650x100px

Document › Details

AstraZeneca plc. (3/17/25). "Press Release: AstraZeneca Enters License Agreement with Alteogen for Subcutaneous Formulations of Multiple Oncology Assets".

	Region	ALL
	Organisation	AstraZeneca plc (LSE: AZN)
	Group	AstraZeneca (Group)
	Organisation 2	Alteogen Inc. (KR)
	Product	ALT-B4 technology (sc injection)
	Product 2	cancer drug
	Index term	AstraZeneca–Alteogen: drug delivery technology, 202503– license ww + supply to use ALT-B4 to develop + market sc formulations of cancer drugs
	Person	Massacesi, Cristian (AstraZeneca 202503 CMO + Oncology Chief Development Officer)
	Person 2	Park, Soon Jae (Alteogen 202503 CEO)

AstraZeneca and Alteogen Inc. have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme™ platform technology. Under the terms of the agreement, AstraZeneca will acquire worldwide rights to use ALT-B4 to develop and commercialise subcutaneous formulations of several oncology assets. Alteogen will be responsible for clinical and commercial supply of ALT-B4 to AstraZeneca.

Subcutaneous formulations have the potential to offer many advantages including time savings for patients, clinical staff, and health systems due to shorter administration times.

Cristian Massacesi, Chief Medical Officer and Oncology Chief Development Officer, AstraZeneca, said: “We are dedicated to advancing new medicines for people with cancer and that includes new methods of delivery which are more convenient for patients, physicians and healthcare systems. We look forward to collaborating with Alteogen on several assets in our portfolio with the goal of bringing new subcutaneous options to patients that can transform the way cancer care is delivered.”

Dr Soon Jae Park, Chief Executive Officer of Alteogen, said: “We are excited to expand our Hybrozyme™ Technology by collaborating with AstraZeneca in their development of novel subcutaneous cancer medicines to meet the needs of patients.”

Financial considerations

AstraZeneca will make an upfront payment to Alteogen and additional payments upon achievement of specific development, regulatory and sales-related milestones. Additionally, Alteogen will receive royalties on the sales of the commercialised products.

The transaction does not impact AstraZeneca’s financial guidance for 2025.

Notes

ALT-B4

ALT-B4 is Alteogen’s proprietary human recombinant hyaluronidase enzyme developed utilizing Hybrozyme™ technology. ALT-B4 can enable the large volume subcutaneous administration of drugs that are typically administered as an IV infusion. ALT-B4 does this by temporarily hydrolyzing hyaluronan in the extracellular matrix.

AstraZeneca in oncology

AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.

The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience.

AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Record changed: 2025-04-10